A century ago, two oddly domestic puzzles helped set the rules for what modern science treats as "real": a Guinness brewer ...

A little over a decade ago, a neuroscientist found "significant activation" in the neural tissue of a dead fish. While it ...

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt ...

Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...

Belite Bio has released topline results from the global phase 3 DRAGON trial of Tinlarebant in patients with Stargardt ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related ...

Belite Bio's Tinlarebant cut lesion growth in a pivotal Stargardt Phase 3 trial, showing strong efficacy and a consistent safety profile.

A/B testing, once heralded as the gold standard for data-driven decision-making, often slows companies down due to an ...

The Schwab Trading Activity Index™ (STAX) increased to 48.75 in November, up from its score of 48.12 in October. The only index of its kind, the STAX is a proprietary, behavior-based index that ...

Secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves overall survival in ...

Research reveals traditional value and growth funds include expensive slow-growing stocks that drag performance by 2% ...